Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00017-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Lindsay M Avery und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cefepime, Pseudomonas aeruginosa, Anti-Bacterial Agents, Enterobacteriaceae. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor that potentiates the in vitro activity of cefepime against Enterobacterales and Pseudomonas aeruginosa strains harboring serine and metallo-β-lactamases. Taniborbactam lacks intrinsic antibacterial activity. An in vitro hollow fiber infection model (HFIM) was used to evaluate bacterial kill and the potential for treatment-emergent resistance associated with the clinical cefepime-taniborbactam dose of 2–0.5 g every 8 h, administered as a 2 h infusion, for 7 days. Nine cefepime-resistant bacterial strains were studied among one Escherichia coli , five Klebsiella pneumoniae , and three P. aeruginosa that harbored a variety of cephalosporinases, extended-spectrum β-lactamases, and carbapenemases with cefepime-taniborbactam MIC values that ranged from 0.25 to 8 µg/mL. All nine strains grew rapidly when treated with cefepime alone, consistent with phenotypic resistance. Human plasma concentration-time profiles for cefepime and taniborbactam were simulated in the HFIM systems and resulted in bactericidal activity (≥3 log 10 CFU/mL reduction) against eight of nine strains when assessed 8 h after initiation of the first dose, and against all nine strains by day 7. Treatment-emergent resistance, defined as bacterial subpopulations with ≥4 times the baseline MIC, was not detected in any cefepime-taniborbactam model from days 1 to 7. Therefore, human cefepime-taniborbactam exposures demonstrated sustained bactericidal activity and suppressed the emergence of resistance in a 7-day HFIM among serine and metallo-β-lactamase-positive Enterobacterales and P. aeruginosa strains. These observations support the clinical development of cefepime-taniborbactam and inform understanding of its potential role in treating serine and/or metallo-β-lactamase-positive Gram-negative bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
ORCID-Profile: Lindsay M Avery, Greg Moeck, Tsuyoshi Uehara
Förderung
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Avery, L. M., Edwards, M., Yi, F., Moeck, G., Uehara, T., & Pevear, D. C. (2025). Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00017-25
Vancouver
Avery LM, Edwards M, Yi F, Moeck G, Uehara T, Pevear DC. Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00017-25
BibTeX
@article{Avery2025,
author = {Avery, Lindsay M and Edwards, Mitchell and Yi, Fan and Moeck, Greg and Uehara, Tsuyoshi and Pevear, Daniel C},
title = {Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00017-25}
}
EUVIMED